Steven R.  Miller net worth and biography

Steven Miller Biography and Net Worth

COO & Chief Scientific Officer of Catalyst Pharmaceuticals
Steven R. Miller, PhD, is responsible for Catalyst’s product development program, which includes all aspects of chemistry and manufacturing controls, quality systems, contract operations, and development planning. Dr. Miller has 25 years of experience in the pharmaceutical and healthcare industries, joining Catalyst in 2007. Most recently he has managed Catalyst’s in-licensing of CPP-115 and Catalyst’s newest drug, Firdapse®, and taken these products through various preclinical and clinical development studies. Dr. Miller previously served as Executive Director for Research and Development Operations at Watson Pharmaceuticals and as Vice President of Research and Product Development at Royce Laboratories; he has also managed medical device development groups at Baxter Diagnostics and worked as an analytical chemist for the U.S. Food and Drug Administration. Dr. Miller received his doctorate in physical organic chemistry at the University of Miami; his work has been published in numerous technical and professional journals including Journal of Analytical Chemistry, Journal of the American Chemical Society, Journal of Medicinal Chemistry, and Chemical Communications.

How old is Steven R. Miller?

Dr. Miller is currently 62 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Dr. Gary Ingenito M.D., Ph.D., Chief Medical & Regulatory Officer, who is 68 years old. Learn More on Steven R. Miller's age.

How do I contact Steven R. Miller?

The corporate mailing address for Dr. Miller and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Steven R. Miller's contact information.

Has Steven R. Miller been buying or selling shares of Catalyst Pharmaceuticals?

Steven R. Miller has not been actively trading shares of Catalyst Pharmaceuticals in the last ninety days. Learn More on Steven R. Miller's trading history.

Who are Catalyst Pharmaceuticals' active insiders?

Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), and Steven Miller (COO & Chief Scientific Officer ). Learn More on Catalyst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Catalyst Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 551,255 shares worth more than $9,231,148.44. The most recent insider tranaction occured on August, 21st when Director David S Tierney sold 15,000 shares worth more than $301,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.

Information on this page was last updated on 8/21/2024.

Steven R. Miller Insider Trading History at Catalyst Pharmaceuticals

See Full Table

Steven R. Miller Buying and Selling Activity at Catalyst Pharmaceuticals

This chart shows Dr. Steven R. Miller's buying and selling at Catalyst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $21.89
Low: $21.68
High: $22.27

50 Day Range

MA: $20.50
Low: $19.37
High: $21.89

2 Week Range

Now: $21.89
Low: $12.27
High: $22.27

Volume

999,346 shs

Average Volume

1,188,807 shs

Market Capitalization

$2.60 billion

P/E Ratio

40.54

Dividend Yield

N/A

Beta

0.76